The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients

This study has been completed.
Information provided by:
CHU de Charleroi Identifier:
First received: July 24, 2006
Last updated: November 30, 2006
Last verified: October 2000
To examine the effects of the addition of clonidine to diuretics on the mobilization of ascites at short-term (diuretic response and requirement of diuretics) and long-term (readmissions for tense ascites and requirement of diuretics) in cirrhotics with increased sympathetic nervous system. Secondary objectives were to study neuro-hormonal,hemodynamic effects and side effects of clonidine and diuretics.

Condition Intervention
Ascitic Cirrhosis
Hyperactivation of Sympathetic Nervous System
Drug: clonidine

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double-Blind
Primary Purpose: Treatment
Official Title: The Effects of Clonidine on the Diuretic Response in Cirrhotic Patients With Ascites and Activation of Sympathetic Nervous System: a Randomized Double-Blind Placebo Controlled Study.

Resource links provided by NLM:

Further study details as provided by CHU de Charleroi:

Estimated Enrollment: 64
Study Start Date: October 2000

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cirrhotic patients with ascites
  • Plasma norepinephrine level > 300 pg/mL (normal value: 185 – 275 pg/mL)

Exclusion Criteria:

  • Serum bilirubin concentration above 4.5 mg/dL
  • Prothrombin time below 40%
  • Platelet count below 40 X 10¨9/liter
  • Serum creatinine concentration above 2 mg/dL
  • Gastro-intestinal hemorrhage
  • Alcoholic hepatitis
  • Diabetes mellitus,
  • Hepatocellular carcinoma
  • Respiratory or cardiac failures
  • Hepatic encephalopathy
  • Bacterial infection
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00356226

ISPPC CHU de Charleroi
Charleroi, Belgium, 6000
Sponsors and Collaborators
CHU de Charleroi
Principal Investigator: Lenaerts Anne, MD ISPPC CHU de Charleroi
  More Information

Publications: Identifier: NCT00356226     History of Changes
Other Study ID Numbers: HEP-05-1550.R2 
Study First Received: July 24, 2006
Last Updated: November 30, 2006
Health Authority: Belgium: Ministry of Social Affairs, Public Health and the Environment

Keywords provided by CHU de Charleroi:

Additional relevant MeSH terms:
Adrenergic Agents
Adrenergic Agonists
Adrenergic alpha-2 Receptor Agonists
Adrenergic alpha-Agonists
Antihypertensive Agents
Autonomic Agents
Cardiovascular Agents
Central Nervous System Agents
Molecular Mechanisms of Pharmacological Action
Neurotransmitter Agents
Peripheral Nervous System Agents
Pharmacologic Actions
Physiological Effects of Drugs
Sensory System Agents
Therapeutic Uses processed this record on February 09, 2016